Objective To find antigens related with hepatocellular carcinoma(HCC).Methods Human Zinc Finger Protein 216(ZNF216) was identified by SEREX(serological analysis of recombinant cDNA expression libraries,SEREX).The 6His fusion protein of ZNF216 was expressed by bacteria and purified with a nickel affinity chromatography column.The level of anti-ZNF216 antibody in the sera was detected by ELISA,andZNF216 mRNA level in HCC tissue and its peripheral normal tissue was detected by RT-PCR.Results The level of anti-ZNF216 antibody in the sera of HCC patients was higher than that of healthy individuals.ZNF216 mRNA level in HCC tissue is evidently higher than peripheral normal tissue.Conclusion The over-expression of ZNF216 in the HCC sera and tissue indicates that ZNF216 perhaps plays a role in HCC.

Objective To compare RNA interference (RNAi) with imatinib in killing K562 cells. Methods Design effective shRNA sequences special for bcr-abl silencing and insert them into the eukaryotic expression vector for RNAi by gene engineering. The recombinant plasmi(ts were then transfected into K562 cells. 48 hours later, the efficiency of transfection was identified by fluorescent microscope, bcr-abl mRNA level was detected by RT-PCR. Another group of K562 cells were treated respectively by imatinib with different concentration. All groups of K562 cells were finally analyzed in apoptosis, cell proliferation and phosphotyrosine-containing proteins. Results Both RNAi and imatinib induced apoptosis, decreased proliferation and reduced phosphotyrosine-containing proteins. Conclusion BNAi can kill K562 cells successfully as imatinib, and it may be a promising way to treat CML patients in clinic, especially for those who fail in imatinib or other chemotherapy.